Mortality Risk Among Frail Neonates and Maternal BCG Vaccine Scar Status: Observational Study From Guinea-Bissau
Overview
Authors
Affiliations
Background: Maternal priming with the Bacille Calmette-Guérin (BCG) vaccine has been associated with reduced offspring mortality rates. We investigated this association in a cohort of frail neonates.
Methods: We performed an observational study within a randomized BCG trial conducted at the neonatal intensive care unit (NICU) in Guinea-Bissau from 2015 to 2017. At NICU admission and after informed consent, the maternal scar status was evaluated by visual inspection before neonates were randomized 1:1 to receive BCG + oral polio vaccine immediately or at hospital discharge. Stratified by maternal scar status, we assessed overall in-hospital and postdischarge mortality rates through 42 days of age in Cox proportional hazards models providing adjusted mortality rate ratios (aMRRs).
Results: Overall, 62% of mothers (903 of 1451) had a BCG vaccine scar. During NICU admission, the mortality risk was 1.7% (15 of 903) for neonates born to mothers with a scar versus 3.3% (18 of 548) for those born to mothers with no scar; the aMRR for maternal scar versus no scar was 0.53 (95% CI, .26-1.05), 0.39 (95% CI, .13-1.05) for unvaccinated and 0.70 (95% CI, .26-1.87) for vaccinated neonates.
Conclusions: This small study indicates that maternal BCG vaccine might be associated with reduced all-cause NICU mortality rate. If confirmed elsewhere, this finding would have substantial ramifications for global health.
Baek O, Schaltz-Buchholzer F, Campbell A, Amenyogbe N, Campbell J, Aaby P Semin Immunopathol. 2024; 46(5):13.
PMID: 39186134 PMC: 11347488. DOI: 10.1007/s00281-024-01022-9.
Schaltz-Buchholzer F, Nielsen S, Sorensen M, Stjernholm E, Fabricius R, Umbasse P Open Forum Infect Dis. 2024; 11(3):ofae057.
PMID: 38500576 PMC: 10946234. DOI: 10.1093/ofid/ofae057.
Thysen S, Borges I, Martins J, Stjernholm A, Hansen J, da Silva L BMJ Glob Health. 2024; 9(2).
PMID: 38350670 PMC: 10862335. DOI: 10.1136/bmjgh-2023-014044.
BCG and SARS-CoV-2-What Have We Learned?.
Kulesza J, Kulesza E, Kozinski P, Karpik W, Broncel M, Fol M Vaccines (Basel). 2022; 10(10).
PMID: 36298506 PMC: 9610589. DOI: 10.3390/vaccines10101641.